Targeting autoantibody production to treat lupus
Silencing autoantibody secretion for SLE therapy
This study is testing a new treatment for people with Systemic Lupus Erythematosus (SLE) that aims to reduce harmful antibodies without affecting the immune cells that help protect against infections, making it a safer option for managing the condition.
Quick facts
| Grant type | Sbir 1 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Larix Bioscience, LLC NIH-funded |
| Lab location | 1 site (Sunnyvale, United States) |
| Project ID | NIH-10838510 on NIH RePORTER |
What this research studies
This research focuses on developing a new therapy for Systemic Lupus Erythematosus (SLE), an autoimmune disorder characterized by harmful autoantibody production. The approach involves silencing the secretion of these autoantibodies without depleting B cells, which are essential for immune protection. By targeting a specific protein called CD79a, the therapy aims to inhibit the immune response that leads to autoantibody formation, potentially offering a safer treatment option for patients. This innovative method seeks to provide a reversible solution that maintains the patient's ability to fight infections while managing their autoimmune condition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with Systemic Lupus Erythematosus who are experiencing issues related to autoantibody production.
Not a fit: Patients with other autoimmune disorders or those who do not have Systemic Lupus Erythematosus may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to a safer and more effective treatment for patients with lupus, reducing harmful autoantibody levels without compromising their immune system.
How similar studies have performed: While the approach of targeting CD79a is innovative, similar strategies in autoimmune therapies have shown promise, suggesting potential for success.
Where this research is happening
Sunnyvale, United States
- Larix Bioscience, LLC — Sunnyvale, United States (Active)
Researchers
- Principal investigator: Mendelsohn, Andrew R — Larix Bioscience, LLC
- Study coordinator: Mendelsohn, Andrew R
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.